大分割放疗后大分割推量联合同步每周化疗治疗不可切除III期非小细胞肺癌:前瞻性II期研究(GASTO-1049)结果
该前瞻性II期研究纳入75例不可切除III期局部晚期非小细胞肺癌患者,接受大分割放疗40 Gy/10次后大分割推量24-28 Gy/6-7次联合同步每周多西他赛25 mg/m2与奈达铂25 mg/m2化疗。中位随访28.0个月,客观缓解率94.7%,中位无进展生存期21.6个月,1年与2年总生存率分别为94.7%和72.4%,急性3级放射性食管炎发生率5.3%,未发生3-5级急性肺炎。
要点
- 大分割放疗后推量联合同步每周化疗的客观缓解率达94.7%,中位无进展生存期21.6个月。
- 1年与2年总生存率分别为94.7%与72.4%,中位总生存期未达到。
- 3级急性放射性食管炎发生率为5.3%,2级放射性肺炎发生率为17.3%,未发生3-5级急性肺炎。
核心结论
- 大分割放疗后大分割推量联合同步每周化疗在局部晚期非小细胞肺癌中可获得满意的局部控制与生存结局,放射性毒性中等。
- 该新型强效大分割同步放化疗方案显著缩短治疗时间,并为联合巩固免疫治疗提供了潜在机会。
研究设计与样本
- 前瞻性II期临床试验(GASTO-1049),于2018年6月至2020年6月招募新诊断的不可切除III期局部晚期非小细胞肺癌患者。
- 患者接受大分割放疗40 Gy分10次,随后大分割推量24-28 Gy分6-7次,联合同步每周化疗多西他赛25 mg/m2与奈达铂25 mg/m2。
- 主要终点为无进展生存期,次要终点包括总生存期、局部区域无失败生存期、无远处转移生存期、客观缓解率和毒性。
主要发现
- 共纳入75例患者,中位随访时间28.0个月,全队列客观缓解率为94.7%。
- 44例(58.7%)患者记录到疾病进展或死亡,中位无进展生存期为21.6个月(95%CI 15.6-27.6个月)。
- 1年与2年无进展生存率分别为81.3%(95%CI 72.5%-90.1%)与43.3%(95%CI 31.5%-55.1%)。
- 末次随访时中位总生存期、无远处转移生存期与局部区域无失败生存期均未达到;1年与2年总生存率分别为94.7%(95%CI 89.6%-99.8%)与72.4%(95%CI 62.0%-82.8%)。
- 最常见的急性非血液学毒性为放射性食管炎,2级与3级急性放射性食管炎分别见于20例(26.7%)与4例(5.3%)患者;13例(13/75,17.3%)发生2级肺炎,随访期间未发生3-5级急性肺炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We launched a prospective phase 2 clinical trial to explore the safety and efficacy of hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Patients with newly diagnosed LA-NSCLC with unresectable stage III disease were recruited between June 2018 and June 2020. Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2 and nedaplatin 25 mg/m2). The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), objective response rate (ORR), and toxicities. RESULTS: From June 2018 to June 2020, 75 patients were enrolled with a median follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease progression or death was recorded in 44 (58.7%) patients, with a median PFS of 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1- and 2-year PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), respectively. The median OS, DMFS, and LRFS had not been reached at the time of the last follow-up. The 1- and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 acute pneumonitis occurred during follow-up. CONCLUSIONS: Hypo-RT followed by hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory local control and survival outcomes with moderate radiation-induced toxicity in patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened treatment time and provided the potential opportunity for the combination of consolidative immunotherapy.
引用
- Zhou R, Qiu B, Xiong M, et al. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049). Int J Radiat Oncol Biol Phys. 2023. PMID: 37100160. doi:10.1016/j.ijrobp.2023.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。